文献速递免疫规划

基于重组单周期黄病毒载体的狂犬病疫苗新方法

A novel approach to a rabies vaccine based on a recombinant single-cycle flavivirus vector.
PubMed 文献 · Vaccine · 2017-09-09

研究将狂犬病病毒G蛋白基因插入西尼罗河病毒复制缺陷型单周期RepliVax®载体,构建RV-RabG候选疫苗;在补体细胞中滴度达8 log10感染颗粒/ml,在新生小鼠中完全无神经毒力,小鼠、犬和猪单剂接种即诱生高滴度狂犬病病毒中和抗体,小鼠和犬攻毒保护,犬免疫后1年和2年均受保护。

要点

  • RV-RabG在补体细胞中复制滴度达8 log10感染颗粒/ml,在正常细胞中表达G蛋白但不扩散。
  • 2-3日龄新生小鼠神经毒力试验显示RV-RabG候选株完全无神经毒力。
  • 小鼠、犬和猪单剂接种即诱生高滴度狂犬病病毒中和抗体,小鼠和犬攻毒后受保护。

核心结论

  • 数据表明RepliVax®技术可作为递送非黄病毒靶抗原的强效载体平台,用于开发候选疫苗。

研究设计与样本

  • 构建多种表达全长狂犬病病毒G蛋白的西尼罗河病毒基单周期RepliVax®载体,并在补体细胞、正常细胞、新生小鼠及小鼠、犬和猪中进行评估。

主要发现

  • RV-RabG构建体在补体细胞中复制滴度达8 log10感染颗粒/ml。
  • RV-RabG感染正常细胞后有效表达狂犬病病毒G蛋白,但不向周围细胞扩散。
  • 狂犬病病毒G蛋白表达稳定,经多轮体外传代后仍维持。
  • 2-3日龄新生小鼠神经毒力试验显示RV-RabG候选株完全无神经毒力。
  • 在小鼠、犬和猪中单剂接种即诱生高滴度狂犬病病毒中和抗体,小鼠和犬攻毒后受保护;犬在免疫后1年和2年均受保护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The RepliVax® vaccine (RV) platform is based on flavivirus genomes that are rationally attenuated by deletion. These single-cycle RV vaccine candidates targeting flavivirus pathogens have been demonstrated to be safe, highly immunogenic, and efficacious in animal models, including non-human primates. Here we show utility of the technology for delivery of a non-flavivirus immunogen by engineering several West Nile-based RV vectors to express full-length rabies virus G protein. The rabies virus G protein gene was incorporated in place of different West Nile structural protein gene deletions. The resulting RV-RabG constructs were demonstrated to replicate to high titers (8 log10 infectious particles/ml) in complementing helper cells. Following infection of normal cells, they provided efficient rabies virus G protein expression, but did not spread to surrounding cells. Expression of rabies virus G protein was stable and maintained through multiple rounds of in vitro passaging. A sensitive neurovirulence test in 2-3 day old neonatal mice demonstrated that RV-RabG candidates were completely avirulent indicative of high safety. We evaluated the RV-RabG variants in several animal models (mice, dogs, and pigs) and demonstrated that a single dose elicited high titers of rabies virus-neutralizing antibodies and protected animals from live rabies virus challenge (mice and dogs). Importantly, dogs were protected at both one and two years post-immunization, demonstrating durable protective immunity. The data demonstrates the potential of the RepliVax® technology as a potent vector delivery platform for developing vaccine candidates against non-flavivirus targets.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Giel-Moloney M, Rumyantsev AA, David F, et al. A novel approach to a rabies vaccine based on a recombinant single-cycle flavivirus vector. Vaccine. 2017. PMID: 28899628. doi:10.1016/j.vaccine.2017.08.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。